CompletedPhase 2NCT01511068
Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
Studying Hereditary pulmonary alveolar proteinosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Principal Investigator
- Bruce Trapnell, MDChildren's Hospital Medical Center, Cincinnati
- Intervention
- Leukine(drug)
- Enrollment
- 2 enrolled
- Eligibility
- 8 years · All sexes
- Timeline
- 2012 – 2014
Study locations (2)
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Virginia Commonwealth University, Richmond, Virginia, United States
Collaborators
Virginia Commonwealth University · Genzyme, a Sanofi Company
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01511068 on ClinicalTrials.govOther trials for Hereditary pulmonary alveolar proteinosis
Additional recruiting or active studies for the same condition.
See all trials for Hereditary pulmonary alveolar proteinosis →